The 2019 HIV and Hepatitis B Cure Forum took place on 20-21st July immediately before the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City this week.
The forum this year included research into curing chronic hepatitis B
infection as well as HIV, as the two viruses share
The roll-out of pre-exposure prophylaxis (PrEP) provides an
opportunity to bring down the incidence of sexually transmitted infections
(STIs), provided that PrEP and STI programmes are better co-ordinated and
integrated, representatives from the World Health Organization (WHO) said yesterday at the 10th International AIDS Society Conference on HIV
Science (IAS 2019) in Mexico City.While
On July 12, the Centers for Disease Control and Prevention published a report that found an “encouraging” increase in recent years in urban-living queer men’s awareness of pre-exposure prophylaxis (PrEP). But in some of the cities covered by the CDC’s report, many people who inject drugs are wholly unaware of the “miracle drug,” as HIV activists have dubbed it.
Vaughan Gething, the Welsh minister for health and social services, said he was “delighted” that access to PrEP was now “fully embedded” into sexual health services.
An experimental drug from Merck & Co may lead the way in the U.S. market, Citi said. Baum estimates MK-8591 may reach sales of $7 billion in HIV. Of that total, $3.5 billion may come from pre-exposure prophylaxis, or PrEP, as the preventative treatments are called.
HIV experts and professionals agree that pre-exposure
prophylaxis (PrEP) is a valuable addition to HIV prevention, but have varied
views of the relationship between PrEP, reduced condom
use and sexually transmitted infections (STIs), according to a study published
last month in the Sociology of Health
& Illness.Professor Martin Holt of the University of New South
Yale University investigators are leading a trial that is testing a bio-behavioral intervention’s ability to improve pre-exposure prophylaxis (PrEP) adherence and reduce the risk of HIV acquisition in individuals with opioid dependency, a population experiencing new outbreaks of HIV.
Gilead should either commit to providing all the doses of PrEP required for everyone who would benefit or open the market up to a range of generic manufacturers.
Yale University investigators are leading a trial that is testing a bio-behavioral intervention’s ability to improve pre-exposure prophylaxis (PrEP) adherence and reduce the risk of HIV acquisition in individuals with opioid dependency, a population experiencing new outbreaks of HIV.
It took universal health care, political will and a health campaign designed to terrify the public, but nearly four decades into the H.I.V. crisis, Australian researchers say the country is on a path toward making transmissions of the virus vanishingly rare.
For a long time, the most common way to describe pre-exposure prophylaxis (PrEP) was that it is a daily pill taken to prevent acquiring HIV. But now, New York City is tackling what might be a barrier to PrEP uptake with its new on-demand PrEP initiative.
Half of gay and bisexual men using PrEP in Australia would
be interested in switching from taking daily PrEP to taking on-demand PrEP, and
this interest was most strongly associated with having sex infrequently and concerns
about long term side effects. The survey was carried out by Dr Vincent Cornelisse and colleagues and
Nine gay men are known to have seroconverted since being put
on a waiting list for pre-exposure prophylaxis (PrEP) at a single Manchester
clinic, Dr Sally Jewsbury told the British Association for Sexual Health and
HIV (BASHH) conference in Birmingham yesterday.Similar cases are likely to have gone undocumented across
England, as a result of
Transgender women and transfeminine nonbinary individuals
suggested a number of key issues that health services need to address in order
to increase the uptake of pre-exposure prophylaxis (PrEP) among transgender people. These included addressing the contextual factors associated with HIV in this
community, developing more inclusive messaging and imagery, healthcare
providers having an ongoing
There is high awareness but low uptake of HIV PrEP (pre-exposure prophylaxis) among black and Latina transgender women in Baltimore and Washington DC, investigators report in the Journal of Acquired Immune Deficiency Syndromes. Although 87% had heard of PrEP, only 17% had taken it. However, three-quarters of HIV-negative individuals who had
No HIV infections occurred over two years of follow-up among
individuals taking event-driven pre-exposure prophylaxis (PrEP) in a
demonstration study conducted in Amsterdam, investigators report in Lancet
HIV. The study recruited MSM and transgender individuals who were given the
option of taking daily or event-based PrEP. Two HIV infections were documented,
both involving individuals who opted
A study of people prescribed pre-exposure prophylaxis (PrEP) over a four-year period at
a large centre in Los Angeles has found that HIV incidence in people taking
PrEP was more than 95% lower than among service users who discontinued PrEP,
and at least 92% lower than among the clinic population in general.These are
Self-perceived HIV risk, learning about pre-exposure
prophylaxis (PrEP) via trusted sources, positive healthcare experiences and
health insurance coverage are facilitators of PrEP initiation and continuation
for at-risk minority women, according to research conducted in New York City
and published in the Journal of the Association of Nurses in AIDS Care.
The investigators identified three distinct phases
